Pharmacokinetic evaluation of piperacillin-tazobactam (Q37773368)

22 August 2017

1 reference

title

Pharmacokinetic evaluation of piperacillin-tazobactam (English)

1 reference

22 August 2017

1 reference

Jason A Roberts

2

0 references

Jeffrey Lipman

object named as

Jeffrey Lipman

series ordinal

4

0 references

David L Paterson

object named as

David L Paterson

series ordinal

3

0 references

author name string

Yoshiro Hayashi

series ordinal

1

1 reference

PubMed ID

20636224

22 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

1017-1031

1 reference

22 August 2017

8

1 reference

Francis Tally and the discovery and development of tigecycline: a personal reminiscence

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Diagnosis and treatment of diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Three decades of beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Determinants of the activity of beta-lactamase inhibitor combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Piperacillin: human pharmacokinetics after intravenous and intramuscular administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Pharmacokinetic issues for antibiotics in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Daily serum piperacillin monitoring is advisable in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.506187

10.1517/17425255.2010.506187

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20636224